WO2011051327A3 - Small antibody-like single chain proteins - Google Patents

Small antibody-like single chain proteins Download PDF

Info

Publication number
WO2011051327A3
WO2011051327A3 PCT/EP2010/066243 EP2010066243W WO2011051327A3 WO 2011051327 A3 WO2011051327 A3 WO 2011051327A3 EP 2010066243 W EP2010066243 W EP 2010066243W WO 2011051327 A3 WO2011051327 A3 WO 2011051327A3
Authority
WO
WIPO (PCT)
Prior art keywords
ascp
bodies
specific
bebd
tebd
Prior art date
Application number
PCT/EP2010/066243
Other languages
French (fr)
Other versions
WO2011051327A2 (en
Inventor
Andreas Loew
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2011051327A2 publication Critical patent/WO2011051327A2/en
Publication of WO2011051327A3 publication Critical patent/WO2011051327A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides a "ASCP-body" that comprises a bottomside epitope binding domain ("BEBD") comprising four Bottomside Binding Regions (BBR1, BBR2, BBR3, and BBR4). This epitope binding domain is in addition to the topside epitope binding domain (TEBD) formed by the three Complementarity Determining Regions (CDR1, CDR2, and CDR3). The invention encompasses mono-specific, bi-specific and multi-specific, and mono-valent, bi-valent and multi-valent ASCP-bodies. The invention also encompasses fusion proteins in which one or more ASCP-bodies with a BEBD is conjugated to one or more ASCP-bodies with a BEBD and, optionally, a TEBD; to one or more ASCP- bodies with a TEBD and, optionally, a BEBD; or to one or more non-ASCP-body entity(ies). The various ASCP-bodies in the bi-specific and multi-specific ASCP-bodies and fusion proteins may all bind to the same epitopes or antigens or may bind to different epitopes or antigens.
PCT/EP2010/066243 2009-10-30 2010-10-27 Small antibody-like single chain proteins WO2011051327A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663809P 2009-10-30 2009-10-30
US61/256,638 2009-10-30

Publications (2)

Publication Number Publication Date
WO2011051327A2 WO2011051327A2 (en) 2011-05-05
WO2011051327A3 true WO2011051327A3 (en) 2011-06-30

Family

ID=43726270

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/066243 WO2011051327A2 (en) 2009-10-30 2010-10-27 Small antibody-like single chain proteins

Country Status (1)

Country Link
WO (1) WO2011051327A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102399288B (en) * 2011-10-19 2013-06-05 山西德丰信成生物科技有限公司 Immunoglobulin Fc (fragment crystalline) targeted single-domain heavy-chain antibody
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US20160168258A1 (en) * 2012-03-13 2016-06-16 Hélène VERHEIJE Bi-specific adapters
FI3174559T3 (en) * 2014-07-29 2023-01-13 Radio-labelled antibody fragments for use in the prevention and/or treatment of cancer
EP3180037A1 (en) 2014-07-29 2017-06-21 Vrije Universiteit Brussel Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
BR122020006918B8 (en) 2014-10-23 2023-01-31 Singh Biotechnology Llc ANTI-STAT3 SINGLE DOMAIN ANTIBODY AND ITS USE, IN VITRO METHODS FOR MEASURING SAID ANTIBODY LEVELS AND FOR DIAGNOSING A DISORDER MEDIATED BY AN INTRACELLULAR COMPONENT, ISOLATED POLYPEPTIDE, AND COMPOSITION COMPRISING SUCH ANTIBODY OR ISOLATED POLYPEPTIDE
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
US11306139B2 (en) * 2015-03-20 2022-04-19 Ablynx N.V. Glycosylated immunoglobulin single variable domains
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3325020B1 (en) 2015-07-17 2022-01-12 Vrije Universiteit Brussel Radiolabelled antibody fragments for use in treating cancer
TWI746473B (en) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 Single domain antibodies directed against intracellular antigens
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7101621B2 (en) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． Single domain serum albumin binding protein
US10844134B2 (en) 2016-11-23 2020-11-24 Harpoon Therapeutics, Inc. PSMA targeting trispecific proteins and methods of use
CN110198955A (en) 2016-11-23 2019-09-03 哈普恩治疗公司 Prostate-specific membrane antigen conjugated protein
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CA3063362A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
EP3694550A4 (en) * 2017-10-11 2021-05-26 Nanjing Legend Biotech Co., Ltd. Compositions and methods for increasing protein half-life in a serum
CR20200196A (en) 2017-10-13 2020-06-05 Harpoon Therapeutics Inc Trispecific proteins and methods of use
SG11202003341UA (en) 2017-10-13 2020-05-28 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
CN108285485B (en) * 2018-01-08 2021-02-02 乌鲁木齐恒康致远生物技术有限公司 anti-PD-1 single-domain antibody and application thereof
US20220017626A1 (en) * 2018-09-21 2022-01-20 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CA3120096A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Cd25 antibodies
CN109942705B (en) * 2019-04-15 2022-10-18 石河子大学 MSTN nano antibody, construction method and application thereof
KR102260478B1 (en) * 2019-08-19 2021-06-02 연세대학교 산학협력단 Composition for dissolving monosodium urate crystal
CN111018985B (en) * 2019-12-06 2021-06-18 南京融捷康生物科技有限公司 Application of single-domain antibody aiming at bovine serum albumin BSA
CN110885375B (en) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 Single-domain antibody specifically aiming at MMP-9 protein zinc ion binding domain, product and application
JP2023527609A (en) 2020-02-21 2023-06-30 ハープーン セラピューティクス，インク． FLT3 binding proteins and methods of use
WO2022031869A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Gp130 binding molecules and methods of use
WO2022098771A1 (en) * 2020-11-03 2022-05-12 Ab Studio Inc. Multispecific antibodies and uses thereof
US12012454B2 (en) * 2021-03-24 2024-06-18 China Medical University Hospital Anti-tumor antigen nanobody and nucleic acid encoding sequence thereof, and uses of the same
EP4314076A1 (en) * 2021-03-31 2024-02-07 Kisoji Biotechnology Inc. Binding agents targeting tumors and/or immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062551A2 (en) * 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN
US20070178082A1 (en) * 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (en) 1985-06-26 1992-08-01 Liposome Co Inc LIPOSOMAS COUPLING METHOD.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69112207T2 (en) 1990-04-05 1996-03-28 Roberto Crea "WALK-THROUGH" MUTAGENESIS.
US7063943B1 (en) 1990-07-10 2006-06-20 Cambridge Antibody Technology Methods for producing members of specific binding pairs
US5843701A (en) 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
US5866344A (en) 1991-11-15 1999-02-02 Board Of Regents, The University Of Texas System Antibody selection methods using cell surface expressed libraries
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK1087013T3 (en) 1992-08-21 2009-05-11 Univ Bruxelles Immunoglobulins without light chains
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
DE19628705A1 (en) 1996-07-08 1998-01-15 Fresenius Ag New oxygen transport agents, hemoglobin-hydroxyethyl starch conjugates containing them, processes for their preparation and their use as blood substitutes
WO2000032823A1 (en) 1998-12-02 2000-06-08 Phylos, Inc. Dna-protein fusions and uses thereof
PT1176195E (en) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Method for controlling the activity of immunologically functional molecule
ES2383332T3 (en) 1999-07-27 2012-06-20 Bristol-Myers Squibb Company Peptide Acceptor Ligation Procedure
US7022479B2 (en) 2000-01-24 2006-04-04 Compound Therapeutics, Inc. Sensitive, multiplexed diagnostic assays for protein analysis
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
PT1522590E (en) 2000-06-28 2009-10-26 Glycofi Inc Methods for producing modified glycoproteins
JP2005502322A (en) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート In vivo incorporation of unnatural amino acids
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE10129369C1 (en) 2001-06-21 2003-03-06 Fresenius Kabi De Gmbh Water soluble antibiotic in the form of a polysaccharide conjugate containing an aminosugar
AU2002310502A1 (en) 2001-06-21 2003-01-08 Phylos, Inc. In vitro protein interaction detection systems
ITMI20011483A1 (en) 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R USE OF COMPOUNDS AS FUNCTIONAL ANTAGONISTS TO CENTRAL DEICANNABINOID RECEPTORS
KR100988949B1 (en) 2001-10-25 2010-10-20 제넨테크, 인크. Glycoprotein compositions
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
KR20050073559A (en) 2002-10-16 2005-07-14 더 스크립스 리서치 인스티튜트 Glycoprotein synthesis
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
JP2006519763A (en) 2002-11-08 2006-08-31 アブリンクス エン．ヴェー． Method of administering therapeutic polypeptides and polypeptides therefor
DE10256558A1 (en) 2002-12-04 2004-09-16 Supramol Parenteral Colloids Gmbh Esters of polysaccharide aldonic acids, process for their preparation and use for coupling to active pharmaceutical ingredients
DE10302520A1 (en) 2003-01-23 2004-08-05 Supramol Parenteral Colloids Gmbh Carbonic acid diester of starch fractions and their derivatives, process for their preparation and use for coupling to active pharmaceutical ingredients
EP1711196A4 (en) 2003-12-05 2011-09-14 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
WO2005092928A1 (en) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
JP4939410B2 (en) 2004-07-06 2012-05-23 バイオレン，インク． Look-through mutagenesis to generate denatured polypeptides with enhanced properties
AR052741A1 (en) 2005-04-08 2007-03-28 Noxxon Pharma Ag NUCLEIC ACIDS FROM UNION TO GHRELIN
EP1934259A2 (en) 2005-10-11 2008-06-25 Ablynx N.V. Nanobodies and polypeptides against egfr and igf-ir

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070178082A1 (en) * 2002-11-08 2007-08-02 Ablynx N.V. Stabilized single domain antibodies
WO2004062551A2 (en) * 2003-01-10 2004-07-29 Ablynx N.V. RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DESMYTER ALINE ET AL: "Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 28, 13 July 2001 (2001-07-13), US, pages 26285 - 26290, XP002190005, ISSN: 0021-9258, DOI: 10.1074/JBC.M102107200 *
HARMSEN M M ET AL: "Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features", MOLECULAR IMMUNOLOGY, vol. 37, no. 10, 1 August 2000 (2000-08-01), PERGAMON, GB, pages 579 - 590, XP027290723, ISSN: 0161-5890, [retrieved on 20000801] *
KOROTKOV KONSTANTIN V ET AL: "Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody.", STRUCTURE, vol. 17, no. 2, 13 February 2009 (2009-02-13), LONDON, ENGLAND, pages 255 - 265, XP025936028, ISSN: 0969-2126 *
KOROTKOV KONSTANTIN V ET AL: "Supplemental Data:Crystal structure of the N-terminal domain of the secretin GspD from ETEC determined with the assistance of a nanobody.", STRUCTURE, 13 February 2009 (2009-02-13), LONDON, ENGLAND, pages 3PP, XP002632826, ISSN: 0969-2126 *
MUYLDERMANS S ET AL: "Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains", TRENDS IN BIOCHEMICAL SCIENCES, vol. 26, no. 4, 1 April 2001 (2001-04-01), ELSEVIER, HAYWARDS, GB, pages 230 - 235, XP004241851, ISSN: 0968-0004, DOI: 10.1016/S0968-0004(01)01790-X *
SAERENS ET AL: "Identification of a Universal VHH Framework to Graft Non-canonical Antigen-binding Loops of Camel Single-domain Antibodies", JOURNAL OF MOLECULAR BIOLOGY, vol. 352, no. 3, 23 September 2005 (2005-09-23), LONDON, GB, pages 597 - 607, XP005052664, ISSN: 0022-2836, DOI: 10.1016/J.JMB.2005.07.038 *
TIJINK BERNARD M ET AL: "Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology", MOLECULAR CANCER THERAPEUTICS, vol. 7, no. 8, 1 August 2008 (2008-08-01), AMERICAN ASSOCIATION OF CANCER RESEARCH, US, pages 2288 - 2297, XP009124410, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-07-2384 *
VINCKE CÉCILE ET AL: "General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 5, 30 January 2009 (2009-01-30), US, pages 3273 - 3284, XP009124408, ISSN: 0021-9258, [retrieved on 20081114], DOI: 10.1074/JBC.M806889200 *

Also Published As

Publication number Publication date
WO2011051327A2 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
WO2011051327A3 (en) Small antibody-like single chain proteins
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
HRP20191462T1 (en) Antibodies directed to her-3 and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
PH12018502623A1 (en) Anti-pd-l1 antibodies and uses thereof
NL300911I2 (en) sarilumab
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
WO2010095031A3 (en) Humanized antibodies that bind to cd19 and their uses
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ718973A (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
PE20141398A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
NZ595464A (en) Alpha-4-beta-7 heterodimer specific antagonist antibody
NZ608206A (en) Antibodies that bind myostatin, compositions and methods
JP2013198490A5 (en)
NZ603581A (en) Anti-gd2 antibodies
ES2776179T3 (en) Antibodies directed against surface determinants of S. aureus
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ712765A (en) Antibodies that bind csf1r
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
JP2017505125A5 (en)
ES2572231T3 (en) Human anti-IL-21 monoclonal antibodies
NZ602040A (en) Anti-lrp6 antibodies
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
JP2014526898A5 (en)
NZ597996A (en) Antibodies against human respiratory syncytial virus (rsv) and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10770836

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10770836

Country of ref document: EP

Kind code of ref document: A2